Appendix 2. Additional Outcomes Reported in Studies

|  |  |  |
| --- | --- | --- |
| Outcome | Raine (2018); United Kingdom | Viapiana (2014); Italy |
| MR prednisone | IR prednisone | Methylprednisolone | Prednisone |
| Time to first flare | PONR | PONR | NR | NR |
| Time to second flare | PONR | PONR | NR | NR |
| CSD (over 26 wk) | 3952 mg (3682-4032) | 4067 mg (3962-4487) | NR | NR |
| CSD (total required for remission) | NR | NR | NRNS | NRNS |
| Patient global VAS of disease activity (at 26 wk) | 30.1 (0-50) | 22.4 (1-70) | NR | NR |
| Reduction of ESR (at 2 wk) | NR | NR | 32.2 | 29.4 |
| Reduction of ESR (at 3 mos) | NR | NR | 28.7 | 30.0 |
| Reduction of ESR (at 26 wk/6 mos) | NRNS | NRNS | 29.4 | 28.5 |
| Reduction of ESR (at 12 mos) | NR | NR | 26.0 | 25.5 |
| Reduction of CRP (at 2 wk) | NR | NR | 16.4 | 23.9 |
| Reduction of CRP (at 3 mos) | NR | NR | 15.6 | 23.7 |
| Reduction of CRP (at 26 wk/6 mos) | 51.6 (27-66) | 82.8 (49-204) | 15.3 | 23.7 |
| Reduction of CRP (at 12 mos) | NR | NR | 9.8 | 21.2 |
| HAQ (at 26 wk) | 0.125 | 1 | NR | NR |
| Improvement in EuroQoL-5D | NRNS | NRNS | NR | NR |
| VFQ-25 in patients with vision loss | PONR | PONR | NR | NR |
| Treatment duration | NR | NR | NRNS | NRNS |

Outcomes reported as means with or without ranges (unless otherwise reported)

Outcome differences not statistically significant between groups unless indicated otherwise

MR = modified release

IR = immediate release

wk = week(s)

mos = months

VAS = visual analog scale (pain)

CSD = cumulative steroid dose

ESR = erythrocyte sedimentation rate, in mm/h

CRP = C-reactive protein, in mg/dL

HAQ = Health Assessment Questionnaire

VFQ-25 = visual function questionnaire

NR = not reported

PONR = Pre-specified outcome but not reported

NRNS = outcome measured and deemed to be not statistically significant, but outcome not reported